Showing 2711-2720 of 4063 results for "".
- Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039https://modernod.com/news/nicox-granted-new-patent-for-ncx-470-extending-exclusivity-in-europe-to-2039/2478471/Nicox announced that the European Patent Office has granted a formulation patent for NCX 470, extending the European exclusivity to 2039. The equivalent U.S. patent has already been granted, and NCX 470 is also covered by granted composition of matter patents. “We are pleased that our form
- Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-ophthalmic-solution-for-the-treatment-of-patients-with-dry-eye-disease/2478473/Aerie Pharmaceuticals announced the commencement of COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 agonist) ophthalmic solution for the treatment of patients with dry eye disease. The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and
- Nova Eye Medical Establishes “AlphaRET” to Fulfill the Commercial Development of 2RThttps://modernod.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/Nova Eye Medical has announced the reorganization of its 2RT assets via the establishment of AlphaRET Pty Ltd. Establishing AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the company to better concentrate its commercialization efforts for 2RT, and delineate th
- Insurers Taking ‘Wait and See’ Approach to COVID-19 in 2021 ACA Exchange Rates: Expertshttps://modernod.com/news/insurers-taking-wait-and-see-approach-to-covid-19-in-2021-aca-exchange-rates-experts/2478454/Most insurers on the Affordable Care Act’s (ACA’s) insurance exchanges aren’t factoring COVID-19 into their 2021 rates or believe the pandemic will have a negligible effect, according to several experts, FierceHealthcare
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
- A 25-Year-Old Man Becomes First in the U.S. to Contract Coronavirus Twicehttps://modernod.com/news/a-25-year-old-man-becomes-first-in-the-u-s-to-contract-coronavirus-twice/2478412/A 25-year-old man in the U.S. state of Nevada has contracted the coronavirus on two separate occasions, a study in the Lancet Infectious Diseases journal showed
- Dell, HP, Lenovo and Acer to Announce New Eyesafe Products at the Blue Light Summit 2020https://modernod.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/Eyesafe, UnitedHealthcare Vision, and TÜV Rheinland Group announced the dates and registration details as well as the initial lineup of companies and thought leaders participating in the Blue Light Summit 2020. This year’s event will be held on Oct. 15, 2020. D
- OOSS Submits Comments to CMS on 2021 Proposed ASC Payment Regulationhttps://modernod.com/news/ooss-submits-comments-to-cms-on-2021-proposed-asc-payment-regulation/2478368/On October 5, OOSS submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its proposed 2021 ASC payment regulation. The comments were submitted on behalf of ASCRS, the American Society of Retinal Specialists (ASRS), and the Society for Excellence in Eyecare (SEE), ac
- iSTAR Medical Reports Positive 6-Month Data for MINIject Devicehttps://modernod.com/news/istar-medical-reports-positive-6-month-data-for-miniject-device/2478354/iSTAR Medical announced that its microinvasive glaucoma surgery (MIGS) device MINIject showed consistently positive safety and efficacy outcomes in a larger patient population from ongoing trials. The pooled analysis reviewed data from over 130 patients implanted with MINIject into the supracilia
- Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-recipient-of-the-2020-joanne-angle-public-health-award/2478320/Fight for Sight and Prevent Blindness announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elam’s study, “Engag